Bionyra Pharma, a Paris and Boston-based clinical-stage biopharma company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch and its €143 million ($165 million) oversubscribed Series A financing
The round is co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in this inaugural funding.
The company received Seed financing from Sofinnova Partners and was co-founded with former Sanofi R&D executive Dr. Frédéric Marrache, who serves as CEO of the company.
“More than half of patients suffering from immune-mediated inflammatory diseases remain inadequately controlled, highlighting a significant need for better treatment options. Across our pipeline, we are selectively modulating immune pathways that are central drivers of disease in indications where current therapies remain insufficient,” says Dr. Marrache, co-founder and CEO of Bionyra.
“We have built Bionyra around assets and targets with clear therapeutic rationale, relevant biology and optimised clinical strategy to develop therapies that will deliver meaningful impact to people who don’t currently have good options,” adds Dr. Marrache.
Founded in 2025, Bionyra is advancing next-generation mono and multispecific antibodies for diseases with high unmet need despite currently available treatments, including atopic dermatitis and inflammatory bowel disease (IBD).
Severe immunological and inflammatory diseases impose a constant toll, as patients live with a high daily burden of pain, fatigue and uncertainty, structuring their lives around flares, hospital visits and treatment setbacks. Current therapies often target single nodes of complex immune networks, limiting depth and durability of response.
Many patients cycle through multiple therapies without achieving sustained relief or meaningful improvements in quality of life, highlighting the need for better therapeutic options that can improve clinical outcomes.
Bionyra is launching with a pipeline of clinical and near-clinical, next-generation anti-inflammatory therapies aimed at delivering first- and best-in-class treatments by combining multi-pronged biology with optimised pharmacokinetics to maximise efficacy and patient benefit, including:
- BYN-002: a TL1A monoclonal antibody with half-life extension (HLE) technology with best-in-class potential in IBD and other TL1A-relevant indications. A Phase 1 study in healthy subjects is fully enrolled.
- BYN-003: a TL1A*IL-23p19 bispecific antibody with HLE technology that entered the clinic in April with a Phase 1 study now underway.
- BYN-001: a IL-25 monoclonal antibody with HLE technology in IND-stage for atopic dermatitis and Type 2 inflammation.
“So many patients suffering from immune-mediated inflammatory diseases still face daily burden due to limited treatment options,” says Mehdi Ainouche, Partner at Jeito Capital. “Bionyra is uniquely positioned to accelerate delivery of highly promising therapies to patients through a focused and well-designed clinical development strategy aimed at rapidly generating clinical validation and addressing key unmet needs like deeper remission and alternatives for non-responders.
“We look forward to supporting Frédéric and the entire Bionyra team as the company reaches a pivotal stage in its development while simultaneously building a scalable pipeline in dermatology and IBD.”
Bionyra’s team is led by Frédéric Marrache, MD, PhD, a former senior pharmaceutical executive with extensive experience in immunology and inflammation.
Prior to joining Bionyra as CEO, Frédéric served as Vice President and Executive Global Project Head for Clinical Development in the Immunology and Inflammation Therapeutic Area at Sanofi, where he led a portfolio of early- to mid-stage drug development programmes focused on immune-mediated diseases. Frédéric holds an MD in gastroenterology, a PhD, and an MBA.
“When we co-founded Bionyra with Frédéric, our conviction in both the company and his leadership was grounded in his deep expertise in immune and inflammatory diseases. Today, that conviction is reflected in a $165 million oversubscribed round backed by an exceptional syndicate of investors who share our belief in this pipeline and the team behind it.
“Looking ahead, we are focused on advancing these programs with the aim of bringing meaningful new treatment options to patients,” says Anta Gkelou, Partner at Sofinnova Partners.
